Bildnachweis: Swiss Biotech Association.
The Swiss Biotech Day 2026 has kicked off in Basel from May 4-5, once again positioning Switzerland at the center of the global biotech dialogue. Over two days more than 3,000 industry leaders, investors and scientists from around the world have gathered to discuss innovation, financing trends and cross-border collaboration in life sciences.
Organized by the Swiss Biotech Association, the event continues to expand its international footprint. A key driver of this development is the Global Village initiative, which has grown significantly in recent years and now brings together over 30 international delegations from all continents — underlining the sector’s increasing interconnectedness.
A central highlight of this year’s conference is the presentation of the Swiss Biotech Report 2026, developed in collaboration with EY and partner organizations. The report points to a strong performance of the Swiss biotech sector in 2025, with record revenues and solid investment activity despite a challenging market environment. Its guiding theme, “talent and tenacity,” resonates throughout the event’s agenda, with multiple sessions focusing on talent development, innovation ecosystems and international partnerships. Beyond data and outlook, the conference also serves as a platform for deal-making and strategic exchange. With a high density of biotech executives, venture capital investors and pharmaceutical partners on site, Basel is once again becoming a hotspot for new collaborations, licensing discussions and financing opportunities.
Another highlight is the presentation of the Swiss Biotech Success Stories Award 2026 to Patrick Aebischer. The award recognizes his outstanding contribution to the development of Switzerland’s biotech ecosystem, spanning research, entrepreneurship and institutional leadership. With strong attendance, increasing international participation and a clear focus on collaboration, the Swiss Biotech Day 2026 underscores its role as one of Europe’s leading life sciences platforms — and as a key meeting point for the global biotech community.
